1. van Leeuwen MA, van Rijswijk MH. Acute phase
proteins in the monitoring of inflammatory disorders. Baillieres
Clin Rheumatol. 1994;8(3):531-552.
2. Schimmelpfennig RW Jr, Chusid MJ. Illnesses associated with
extreme elevation of the erythrocyte sedimentation rate in children. Clin Pediatr
(Phila). 1980;19(3):175-178.
3. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands,
receptors and role in inflammation. Clin Immunol. 2005;117(2):104-111.
4. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic
studies of radioiodinated human C-reactive protein in health and
disease. J Clin Invest. 1993;91(4):1351-1357.
5. Becton DL, Raymond L, Thompson C, Berry DH. Acute-phase reactants
in sickle cell disease. J Pediatr. 1989;115(1):99-102.
6. Docci D, Bilancioni R, Buscaroli A, et al. Elevated serum
levels of C-reactive protein in hemodialysis patients. Nephron. 1990;56(4):364-367.
7. Pepys MB. C-reactive protein fifty years on. Lancet. 1981;1(8221):653-657.
8. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates
thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98(9):2720-2725.
9. Jones OY, Spencer CH, Bowyer SL, Dent PB, Gottlieb BS, Rabinovich
CE. A multicenter case-control study on predictive factors distinguishing childhood
leukemia from juvenile rheumatoid arthritis. Pediatrics. May
2006;117(5):e840-e844.
10. Cassidy JT, Valkenburg HA. A five year prospective study
of rheumatoid factor tests in juvenile rheumatoid arthritis. Arthritis
Rheum. 1967;10(2):83-90.
11. Ferucci ED, Majka DS, Parrish LA, et al. Antibodies against
cyclic citrullinated peptide are associated with HLA-DR4 in simplex
and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis
Rheum. 2005;52(1):239-246.
12. Young KA, Parrish LA, Zerbe GO, et al. Perinatal and early
childhood risk factors associated with rheumatoid factor positivity
in a healthy paediatric population. Ann Rheum Dis. 2007;66(2):179-183.
13. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH.
Patterns of clinical remission in select categories of juvenile
idiopathic arthritis. Arthritis Rheum. Nov 2005;52(11):3554-3562.
14. Adib N, Silman A, Thomson W. Outcome following onset of
juvenile idiopathic inflammatory arthritis: II. predictors of outcome
in juvenile arthritis.
Rheumatology (Oxford). 2005;
44(8):1002-1007.
[PubMed: 15827044]
15. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang
M. Disease course and outcome of juvenile rheumatoid arthritis in
a multicenter cohort. J Rheumatol. 2002;29(9):1989-1999.
16. Hanson V, Drexler E, Kornreich H. The relationship of rheumatoid
factor to age of onset in juvenile rheumatoid arthritis. Arthritis
Rheum. 1969;12(2):82-86.
17. Shlomchik MJ, Marshak-Rothstein A, Wolfowicz CB, Rothstein
TL, Weigert MG. The role of clonal selection and somatic mutation
in autoimmunity. Nature. 1987;328(6133):805-811.
18. Borretzen M, Randen I, Zdarsky E, Forre O, Natvig JB, Thompson
KM. Control of autoantibody affinity by selection against amino
acid replacements in the complementarity-determining regions. Proc
Natl Acad Sci USA. 1994;91 (26):12917-12921.
19. Eichenfield AH, Athreya BH, Doughty RA, Cebul RD. Utility
of rheumatoid factor in the diagnosis of juvenile rheumatoid arthritis. Pediatrics. 1986;78(3):480-484.
20. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific
autoantibodies precede the symptoms of rheumatoid arthritis: a study
of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380-386.
21. van Gaalen F, Ioan-Facsinay A, Huizinga TW, Toes RE. The
devil in the details: the emerging role of anticitrulline autoimmunity
in rheumatoid arthritis. J Immunol. 2005;175(9):5575-5580.
22. Dewint P, Hoffman IE, Rogge S, et al. Effect of age on prevalence
of anticitrullinated protein/peptide antibodies in polyarticular
juvenile idiopathic arthritis. Rheumatology (Oxford). 2006;45(2):204-208.
23. Kuhn KA, Kulik L, Tomooka B, et al. Antibodies against citrullinated
proteins enhance tissue injury in experimental autoimmune arthritis. J Clin
Invest. 2006;116(4):961-973.
24. Osborn TG, Patel NJ, Moore TI, Zuckner J. Use of the HEp-2
cell substrate in the detection of antinuclear antibodies in juvenile
rheumatoid arthritis. Arthritis Rheumatol. 1984;27(11):1286-1289.
25. Arroyave CM, Giambrone MJ, Rich KC, Walaszek M. The frequency
of antinuclear antibody (ANA) in children by use of mouse kidney
(MK) and human epithelial cells (HEp-2) as substrates. J
Allergy Clin Immunol. 1988;82(5 Pt 1):741-744.
26. Cabral DA, Petty RE, Fung M, Malleson PN. Persistent antinuclear
antibodies in children without identifiable inflammatory rheumatic
or autoimmune disease. Pediatrics. 1992;89(3):441-444.
27. Malleson PN, Sailer M, Mackinnon MJ. Usefulness of antinuclear
antibody testing to screen for rheumatic diseases.
Arch
Dis Child. 1997; 77(4):299-304.
[PubMed: 9389231]
28. McGhee JL, Kickingbird LM, Jarvis JN. Clinical utility of
antinuclear antibody tests in children.
BMC Pediatrics. 9
2004;4:13.
[PubMed: 15245579]
29. Deane PM, Liard G, Siegel DM, Baum J. The outcome of children
referred to a pediatric rheumatology clinic with a positive antinuclear
antibody test but without an autoimmune disease. Pediatrics. 1995;95(6):892-895.
30. Spencer-Green G. Outcomes in primary Raynaud phenomenon:
a meta-analysis of the frequency, rates, and predictors of transition
to secondary diseases. Arch Intern Med. 1998;158(6):595-600.
31. Lyons R, Narain S, Nichols C, Satoh M, Reeves WH. Effective
use of autoantibody tests in the diagnosis of systemic autoimmune
disease.
Ann NY Acad Sci. 2005;1050:217-228.
[PubMed: 16014537]
32. Egner W. The use of laboratory tests in the diagnosis of
SLE. J Clin Pathol. 2000;53(6):424-432.
33. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of
complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum
Dis. 1986;45(5):359-366.
34. Buyon JP, Winchester RJ, Slade SG, et al. Identification
of mothers at risk for congenital heart block and other neonatal
lupus syndromes in their children. Comparison of enzyme-linked immunosorbent
assay and immunoblot for measurement of anti-SS-A/Ro and
anti-SS-B/La antibodies. Arthritis Rheum. 1993;36(9):1263-1273.
35. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus.
Ann
NY Acad Sci. 2007;1108: 166-182.
[PubMed: 17893983]
36. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin
response in acute infections. Clin Immunol Immunopathol. Oct 1986;41(1):8-15.
37. Male C, Lechner K, Eichinger S, et al. Clinical significance
of lupus anticoagulants in children. J Pediatr. 1999;134(2):199-205.
38. Kamat AV, D’Cruz DP, Hunt BJ. Managing antiphospholipid
antibodies and antiphospholipid syndrome in children. Haematologica. 2006;91(12):1674-1680.
39. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies
against neutrophils and monocytes: tool for diagnosis and marker
of disease activity in Wegener’s granulomatosis. Lancet. 1985;1(8426):425-429.
40. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic
antibodies. Lancet. 2006;368(9533): 404-418.
41. Aguero-Rosenfeld ME, Wang, G, Schwartz I, Wormser GP. Diagnosis
of Lyme Borreliosis.
Clinl Microbiol Rev. 2005;
18:484–509.
[PubMed: 16020686]
42. Shmerling RH, Delbanco TL, Tosteson AN, Trentham DE. Synovial
fluid tests. What should be ordered? JAMA. 1990;264(8):1009-1014.
43. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies
in HLA-B27 positive and negative blood donors. Arthritis
Rheum. 1998;41(1):58-67.
44. Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining
the complex rheumatoid arthritis phenotype based on specificity
of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis
Rheum. 2005;52 (11):3433-3438.
45. Irigoyen P, Lee AT, Wener MH, et al. Regulation of anti-cyclic
citrullinated peptide antibodies in rheumatoid arthritis: contrasting
effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum. 2005;52(12):3813-3818.
46. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory
back pain in ankylosing spondylitis: a reassessment of the clinical
history for application as classification and diagnostic criteria. Arthritis
Rheum. 2006;54(2):569-578.
47. Ho A, Barr SG, Magder LS, Petri M. A decrease in complement
is associated with increased renal and hematologic activity in patients
with systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2350-2357.
48. Buchmann RF, Jaramillo D. Imaging of articular disorders
in children. Radiol Clin North Am. 2004;42(1):151-168,
vii.
49. Gotway MB, Araoz PA, Macedo TA, et al. Imaging findings
in Takayasu’s arteritis. AJR Am J Roentgenol. 2005;184(6):1945-1950.
50. Kimball AB, Summers RM, Turner M, et al. Magnetic resonance
imaging detection of occult skin and subcutaneous abnormalities
in juvenile dermatomyositis. Implications for diagnosis and therapy. Arthritis
Rheum. 2000;43(8):1866-1873.
51. Chan WP, Liu GC. MR imaging of primary skeletal muscle diseases
in children. AJR Am J Roentgenol. 2002;179(4):989-997.
52. Gotway MB, Freemer MM, King TE Jr. Challenges in pulmonary
fibrosis. 1: Use of high resolution CT scanning of the lung for
the evaluation of patients with idiopathic interstitial pneumonias. Thorax. 2007;62(6):546-553.
53. Benseler SM, Silverman ED. Neuropsychiatric involvement
in pediatric systemic lupus erythematosus. Lupus. 2007;16(8):564-571.